Clinical Trials Logo

Spondylarthritis clinical trials

View clinical trials related to Spondylarthritis.

Filter by:

NCT ID: NCT04655612 Completed - COVID-19 Clinical Trials

Seroprevalence Study of CoV-2-SARS (COVID-19) Infection in Patients With Chronic Inflammatory Rheumatic Diseases

COVID-RIC1
Start date: December 1, 2020
Phase:
Study type: Observational

The prevalence of SARS-CoV-2 infection in chronic inflammatory rheumatic diseases has not yet been widely reported, and has been evaluated only in symptomatic patient samples. The proportion of asymptomatic or mildly symptomatic patients is unknown, in patients who share common symptoms with CoV-2-SARS infection. Our objective is to describe the prevalence of seroconversion to CoV-2-SARS by consecutive screening in routine care of patients with chronic inflammatory rheumatism with serological testing

NCT ID: NCT04507659 Completed - Clinical trials for Ankylosing Spondylitis

Jaktinib Hydrochloride Tablets In The Treatment of Active Ankylosing Spondylitis

AS
Start date: December 1, 2020
Phase: Phase 2
Study type: Interventional

This trial uses a multi-center, randomized, double-blind, placebo, parallel-controlled design, and it is expected that about 105 cases will be enrolled in about 10 sites.

NCT ID: NCT04485078 Completed - Clinical trials for Axial Spondyloarthritis

Investigation of Central Sensitization Frequency and Related Factors in Axial Spondyloarthritis Patients

Start date: October 20, 2019
Phase:
Study type: Observational

The term axial spondyloarthritis (axSpA) describes a group of chronic inflammatory diseases that characterized with spinal involvement. AxSpA is one of the most common rheumatic diseases and chronic pain and morning stiffness are the main complaints of these patients. Central sensitization is defined as increased response to normal or sub-threshold stimuli of central nervous system and its close relationship with many rheumatological diseases has been demonstrated in several studies. Pain in axSpA patients is generally considered as a result of increased inflammatory burden and structural changes, However, failure to adequate analgesia in every patient whose inflammation is suppressed with anti-inflammatory treatment suggests new pain mechanisms. Central sensitization (CS) is one of these mechanisms and its recognition is only possible by detailed evaluation of the patient. There is no method for the diagnosis of central sensitization is accepted as a gold standard. clinical scales and quantitative sensory testing (QST) widely is used for this purpose widely. The most commonly used QST types include pressure pain threshold (PPT), temporal summation (TS) and conditioned pain modulation (CPM). The well-known scale used for the evaluation of central sensitization is the Central Sensitization Inventory , developed by Mayer et.al in 2011 for detect central sensitization in chronic pain patients. The aim of this study is to evaluate the frequency of central sensitization (CS) in patients with axSpA by means of clinical scales and quantitative sensory testing (QST), to examine related comorbidities and the parameters associated with the development of sensitization in these patients.

NCT ID: NCT04483648 Completed - Spondyloarthritis Clinical Trials

Cervical Stabilization Exercises in Patients With Spondyloarthritis

Start date: September 1, 2019
Phase: N/A
Study type: Interventional

The aim of this study is to investigate the effectiveness of cervical stabilization exercises on cervical positioning error in spondyloarthritis patients.

NCT ID: NCT04481139 Completed - Clinical trials for Ankylosing Spondylitis

A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Ankylosing Spondylitis

Start date: October 14, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

This study is to evaluate the efficacy and safety of different doses of JAK1 inhibitor SHR0302 in subjects with active ankylosing spondylitis.

NCT ID: NCT04369651 Completed - Spondyloarthritis Clinical Trials

Socio-economic Determinants for Acceptance and Choice of Biological Treatment

Start date: June 1, 2015
Phase:
Study type: Observational

This was a cross-sectional study conducted at National center for rheumatic diseases, Nepal on SpA patient refractory to initial treatment with conventional anti rheumatic drugs. Patients taking TNFi (tumor necrosis factor inhibitor- adalimumab or etanercept) or tofacitinib were included. Baseline demographic, socio-economic, clinical data were recorded.

NCT ID: NCT04368494 Completed - Arthritis Clinical Trials

Exercise Therapy in Patients With Axial Spondyloarthritis

ExTASI
Start date: October 1, 2021
Phase: N/A
Study type: Interventional

Regular exercise, such as brisk walking, has been shown to lower levels of indicators of inflammation in the blood in people with long term conditions. This includes people with heart disease, kidney disease and diabetes. Axial Spondyloarthritis (axSpA) is an inflammatory condition with prescribed medication focusing on reducing inflammation. However, the effect of exercise on indicators of inflammation in axSpA is unknown. The research study intends to investigate whether a 12-week period of regular exercise can have favourable effects on inflammatory markers in the blood.

NCT ID: NCT04360785 Completed - Spondyloarthritis Clinical Trials

Effect of Two Methotrexate in Sync With the First Adalimumab to Prevent the Immunisation Anti Ada in Spondyloarthritis

MESYNAD
Start date: November 11, 2020
Phase: N/A
Study type: Interventional

Preliminary report have demonstrated that methotrexate induces an anti bio-medicament tolerization whan administrated just before the first administration of the bio-medicament. Once this tolerization is obtained it seems useless to continue the methotrexate because this treatment has no efficacity in cases of spondyloarthritis.

NCT ID: NCT04285229 Completed - Spondyloarthritis Clinical Trials

A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis

Start date: April 10, 2020
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in Chinese participants with radiographic axial spondyloarthritis (r-axSpA).

NCT ID: NCT04212806 Completed - Clinical trials for Ankylosing Spondylitis

French Validation of Axial Spondyloarthritis Questionnaires (Val-SpA)

Val-SpA
Start date: January 27, 2020
Phase:
Study type: Observational

The aim is to do a French linguistic validation of three questionnaires used in axial Spondyloarthritis (BASFI, BAS-G, Dougados Functional Index). In order to validate the questionnaires, a prospective, qualitative, observational and monocentric study will be conducted.